
Aerpio Pharmaceuticals, Inc. EBITDA 2011-2026 | ARPO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -6.22 M | -22.4 M | -11.1 M | -21.3 M | -29.5 K | -23 K | -22.8 K | -22.4 K | -23.6 K | -20.5 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.5 K | -22.4 M | -6.12 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-6.4 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.7 | 3.03 % | $ 452 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
BioNTech SE
BNTX
|
-1.4 B | $ 92.14 | 1.33 % | $ 22.3 B | ||
|
Coherus BioSciences
CHRS
|
-180 M | $ 1.61 | 2.55 % | $ 189 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.5 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-11.9 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
-10.1 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | ||
|
Affimed N.V.
AFMD
|
-107 M | - | -34.95 % | $ 21.5 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-14.7 M | $ 0.72 | -0.37 % | $ 32.9 M | ||
|
Esperion Therapeutics
ESPR
|
60.4 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
3.2 M | $ 32.59 | -6.89 % | $ 877 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
Forte Biosciences
FBRX
|
-70.6 M | $ 21.59 | -1.86 % | $ 280 M | ||
|
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
-137 M | - | - | $ 344 M | ||
|
IMV
IMV
|
-10.9 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Grifols, S.A.
GRFS
|
1.19 B | $ 7.98 | -1.6 % | $ 5.42 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-8.42 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-96.7 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
-566 M | - | - | $ 3.37 B | ||
|
Compugen Ltd.
CGEN
|
31.8 M | $ 2.8 | 7.28 % | $ 262 M | ||
|
Anika Therapeutics
ANIK
|
-5.68 M | $ 14.88 | -0.93 % | $ 213 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.4 | -1.16 % | $ 5.6 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M |